The global Myeloproliferative Disorders Drugs market size is expected to be worth around US$ 10.13 billion by 2030, according to a new report by Vision Research Reports.
The global Myeloproliferative Disorders Drugs market size was valued at US$ 8.35 billion in 2020 and is anticipated to grow at a CAGR of 3.10% during forecast period 2021 to 2030.
The presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in the second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.
Chronic myeloproliferative disorders are rare hematological malignances that involve the abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.
There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to the presence of a large target population.
The market is segmented into Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-negative myeloproliferative neoplasms (Ph- MPNs). The latter can be further divided into myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Incidence rates of myeloproliferative disorders are the highest in North America and Western Europe and lowest in East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the disease can occur in any age group.
Myelofibrosis (MF) is a disorder of bone marrow in which the proliferation of abnormal bone marrow stem cells results in fibrosis or replacement of the marrow with collagenous scar tissue. MF includes primary myelofibrosis (PMF) as well as myelofibrosis transformation from prior polycythemia vera (post-PV MF) or essential thrombocytosis (post-ET MF). Polycythemia vera (PV) is characterized by the uncontrolled proliferation of red blood cells. An elevation in hemoglobin leads to increased blood volume and viscosity, and an elevated rate of thrombosis. Essential thrombocythemia (ET) is characterized by an elevation in platelet count and a tendency towards vascular occlusive events and hemorrhage. Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm characterized by uncontrolled proliferation of granulocytes and the BCR-ABL1 fusion gene located in the Philadelphia chromosome. CML is classified as the Philadelphia chromosome-positive MPN.
Allogeneic bone marrow transplantation (BMT) is a potentially curative treatment in the early stage of myeloproliferative disorders, although relapses and mortality from complications such as chronic graft-vs-host disease (GVHD) may occur after transplantation. Less than 10.0% of patients undergo the procedure owing to the presence of severe comorbidities, advanced age, or lack of donors. Standards of care are targeted agents such as Gleevec, Tasigna, and Sprycel for CML and Jakafi for MF and PV along with generic chemotherapeutics such as busulfan and hydroxyurea.
The treatment landscape for myeloproliferative disorders patients has undergone multiple changes since the approval of Gleevec and Jakafi for CML and MF, respectively. Opportunities remain in the Ph- MPNs setting where there exist unmet needs for a safer drug than Jakafi with higher cure rates as well as treatment options for patients who are Jakafi intolerant. Therapeutic development in the second-line setting of Jakafi intolerant patients is estimated to have a major impact on the MF and PV market. Currently, there are no drugs approved for patients who are refractory or become unresponsive to Jakafi treatment. Novel agents are likely to be introduced in later-lines of treatment to target major unmet needs including overcoming tumor resistance, improving progression-free survival, and maintaining the quality of life.
The U.S. dominated the global myeloproliferative disorders drugs market in 2020, followed by Germany. The country is anticipated to maintain its leading position until 2023. Multiple product launches during the forecast period, increasing adoption of novel therapeutics, and the presence of a large target population are among the primary growth stimulants for the market in the U.S.
Novartis AG; Bristol-Myers Squibb Company; Pfizer Inc.; Takeda Pharmaceutical Company Limited; Incyte Corporation; Teva Pharmaceutical Industries Ltd.
The Myeloproliferative Disorders Drugs market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Myeloproliferative Disorders Drugs market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Myeloproliferative Disorders Drugs market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myeloproliferative Disorders Drugs market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Myeloproliferative Disorders Drugs market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Myeloproliferative Disorders Drugs capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Myeloproliferative Disorders Drugs by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Myeloproliferative Disorders Drugs market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Myeloproliferative Disorders Drugs market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Myeloproliferative Disorders Drugs market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Myeloproliferative Disorders Drugs industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Myeloproliferative Disorders Drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Myeloproliferative Disorders Drugs market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Myeloproliferative Disorders Drugs market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Myeloproliferative Disorders Drugs market. These factors have benefited the growth of the global market for Myeloproliferative Disorders Drugs. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Myeloproliferative Disorders Drugs. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Myeloproliferative Disorders Drugs are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Telemedicine Market (By Component: Product, Services; By Technology: Store and forward, Real time, Others; By Application: Teleradiology, Telepsychiatry; By Delivery Mode; By Type: Tele-hospital, Tele-home; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Telehealth Market (By Type: Hardware, Software, & Services; By Application: Telemedicine, Patient Monitoring, Continuous Medical Education, & Others; By Modality: Store-and-Forward, Real-Time, & Remote Patient Monitoring; By Mode of Delivery: Cloud-Based & On-Premises; By End-Users: Healthcare Facilities, Homecare, & Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Ophthalmology Surgical Devices Market (By Product: Cataract Surgery Devices (Intraocular Lenses (IOLs), Ophthalmic Viscoelastic Devices), Glaucoma Surgery Devices, Vitreoretinal Surgery Devices, Refractive Surgery Devices; By End use: Hospitals, Ambulatory Surgical Centers, Ophthalmic Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Cell Culture Market (By Product: Instrument and Consumables; By Application: Stem Cell Technology, Cancer Research, Drug Screening & Development, Tissue Engineering & Regenerative Medicine and Others; By End User: Research Institutes, Pharmaceutical &x Biotechnology Companies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Microscopy Devices Market (By Product Type: Optical Microscopy, Scanning Probe Microscopy, Electron Microscopy, Microscopy Accessories; By Application: Cell and Molecular Biology, Pharmacology and Toxicology, Clinical Pathology and Diagnostics, Surgery, Biomedical Engineering, Neuroscience; By End use: Hospitals, Diagnostic Laboratories, Ambulatory Surgery Centers (ASCs), Physician Offices, and Academic & Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...